Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Descending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68084-0924-11 68084-0924 Tamoxifen Citrate Tamoxifen Citrate 10.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral May 3, 2016 July 31, 2018 No Longer Used
68084-0924-21 68084-0924 Tamoxifen Citrate Tamoxifen Citrate 10.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral May 11, 2016 July 31, 2018 No Longer Used
68084-0935-11 68084-0935 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral May 4, 2016 July 31, 2018 No Longer Used
68084-0935-21 68084-0935 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral May 16, 2016 July 31, 2018 No Longer Used
70518-1881-00 70518-1881 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Feb. 19, 2019 March 8, 2019 No Longer Used
70518-2721-00 70518-2721 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral May 1, 2020 In Use
51862-0446-01 51862-0446 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug. 3, 2016 Oct. 31, 2021 In Use
51862-0446-05 51862-0446 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug. 3, 2016 March 31, 2020 In Use
51862-0446-10 51862-0446 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug. 3, 2016 In Use
51862-0446-30 51862-0446 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug. 3, 2016 In Use
60429-0910-30 60429-0910 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Sept. 28, 2016 Feb. 28, 2023 No Longer Used
68071-3494-03 68071-3494 Tamoxifen Citrate Tamoxifen Citrate 10.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug. 28, 2023 In Use
72162-2208-06 72162-2208 Tamoxifen Citrate Tamoxifen Citrate 10.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan. 5, 2024 In Use
72162-2209-03 72162-2209 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan. 5, 2024 In Use
57894-0469-01 57894-0469 Talquetamab TALVEY 3.0 mg/1.5mL Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 Subcutaneous Aug. 9, 2023 In Use
57894-0470-01 57894-0470 Talquetamab TALVEY 40.0 mg/mL Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 Subcutaneous Aug. 9, 2023 In Use
55513-0078-01 55513-0078 Talimogene Laherparepvec Imlygic 1000000.0 [PFU]/mL Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus Intralesional Nov. 2, 2015 In Use
55513-0079-01 55513-0079 Talimogene Laherparepvec Imlygic 100000000.0 [PFU]/mL Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus Intralesional Nov. 2, 2015 In Use
00069-1501-30 00069-1501 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jan. 31, 2022 In Use
00069-1751-30 00069-1751 Talazoparib Talzenna 0.75 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jan. 31, 2022 In Use
00069-1031-30 00069-1031 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
00069-1235-30 00069-1235 Talazoparib Talzenna 0.35 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
63539-0051-30 63539-0051 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
72187-0401-01 72187-0401 Tagraxofusp Elzonris 1000.0 ug/mL Immunotherapy Fusion Protein IL3/ CD123 Intravenous Jan. 18, 2019 In Use
73535-0208-01 73535-0208 Tafasitamab-cxix MONJUVI 200.0 mg/5mL Immunotherapy Monoclonal Antibody CD19 Intravenous Aug. 5, 2020 In Use

Found 10,000 results in 6 milliseconds — Export these results